444 related articles for article (PubMed ID: 29051325)
1. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
3. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
[TBL] [Abstract][Full Text] [Related]
6. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.
Dhoot DS; Moini H; Reed K; Du W; Vitti R; Berliner AJ; Singh RP
Eye (Lond); 2023 Jul; 37(10):2020-2025. PubMed ID: 35440699
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
8. Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies.
Korobelnik JF; Lu C; Katz TA; Dhoot DS; Loewenstein A; Arnold J; Staurenghi G
Ophthalmol Retina; 2019 Aug; 3(8):663-669. PubMed ID: 31103642
[TBL] [Abstract][Full Text] [Related]
9. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
Ruiz-Moreno JM
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
Brown DM; Wykoff CC; Boyer D; Heier JS; Clark WL; Emanuelli A; Higgins PM; Singer M; Weinreich DM; Yancopoulos GD; Berliner AJ; Chu K; Reed K; Cheng Y; Vitti R
JAMA Ophthalmol; 2021 Sep; 139(9):946-955. PubMed ID: 34351414
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies.
Mitchell P; McAllister I; Larsen M; Staurenghi G; Korobelnik JF; Boyer DS; Do DV; Brown DM; Katz TA; Berliner A; Vitti R; Zeitz O; Metzig C; Lu C; Holz FG
Ophthalmol Retina; 2018 Oct; 2(10):988-996. PubMed ID: 31047501
[TBL] [Abstract][Full Text] [Related]
13. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M
Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552
[TBL] [Abstract][Full Text] [Related]
14. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
[TBL] [Abstract][Full Text] [Related]
15. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.
Gonzalez VH; Boyer DS; Schmidt-Erfurth U; Heier JS; Gordon C; Benz MS; Marcus DM; Sabates NR; Vitti R; Kazmi H; Berliner AJ; Soo Y; Zhu X; Moini H; Zeitz O; Sandbrink R; Do DV
Retina; 2015 Apr; 35(4):687-94. PubMed ID: 25621943
[TBL] [Abstract][Full Text] [Related]
16. Retinal Fluid Volatility Associated With Interval Tolerance and Visual Outcomes in Diabetic Macular Edema in the VISTA Phase III Trial.
Ehlers JP; Uchida A; Sevgi DD; Hu M; Reed K; Berliner A; Vitti R; Chu K; Srivastava SK
Am J Ophthalmol; 2021 Apr; 224():217-227. PubMed ID: 33253664
[TBL] [Abstract][Full Text] [Related]
17. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.
Wykoff CC; Ou WC; Khurana RN; Brown DM; Lloyd Clark W; Boyer DS;
Br J Ophthalmol; 2018 May; 102(5):631-636. PubMed ID: 28814412
[TBL] [Abstract][Full Text] [Related]
19. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy.
Alagorie AR; Velaga S; Nittala MG; Yu HJ; Wykoff CC; Sadda SR
Ophthalmol Retina; 2021 May; 5(5):409-419. PubMed ID: 32882447
[TBL] [Abstract][Full Text] [Related]
20. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]